 Amryt Pharma PLC AIM:AMYT, NASDAQ:AMYT announced revenue growth of 14.6 for the third quarter after sales of its lipodystrophy treatment metreleptin soared 21.5. Revenue rose to US56.5mln in the three months to end-September from US49.3mln in the same period last year. 